| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4185777 | European Psychiatry | 2006 | 4 Pages |
Abstract
The objective of this study was to assess switching to amisulpride (AMS) in treatment-resistant schizophrenia. Seven male subjects were switched to AMS and followed for 8 weeks. PANSS scores improved from 123 to 66 over this period. We conclude that AMS is of interest in the treatment of refractory schizophrenia.
Related Topics
Health Sciences
Medicine and Dentistry
Psychiatry and Mental Health
Authors
V.P. Kontaxakis, B.J. Havaki-Kontaxaki, P.P. Ferentinos, K.G. Paplos, C.R. Soldatos,